Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Biomaterials. 2015 May 31;62:176–187. doi: 10.1016/j.biomaterials.2015.05.046

Table 1.

Biophysical characterization of CPT, CPT-VE, and CPT-S-S-VE nanoformulations

Molar ratio DLC (%) DLE (%) Size (nm) PDI Stability Zeta potential (mv)
PEG5K-VE2/CPT 15:1 0.30 79.6 52.3±2.8 0.24 3 days 1.35±0.02
PEG5K-Fmoc-VE2/CPT 7.5:1 0.65 85.3 76.4±3.6 0.25 8 days 0.87±0.06
PEG5K-VE2/CPT-VE 0.75:1 4.7 72.5 85.4±3.5 0.23 5 days −1.22±0.32
1:1 4.3 83.8 52.3±2.2 0.21 7 days −1.03±0.13
PEG5K-VE2/CPT-S-S-VE 0.5:1 6.2 71.7 62.2±2.4 0.24 7 days −0.66±0.08
0.75:1 5.3 85.4 48.6±1.8 0.22 12 days 0.16±0.03
PEG5K-Fmoc-VE2/CPT-VE 0.5:1 6.6 76.2 93.2±4.5 0.26 21 days −1.29±0.18
0.75:1 5.4 89.1 87.4±4.6 0.22 30 days −0.95±0.21
PEG5K-Fmoc-VE2/CPT-S-S-VE 0.25:1 9.2 70.6 81.5±3.9 0.20 31 days −1.03±0.25
0.5:1 6.8 83.5 57.6±2.1 0.17 62 days −0.78±0.14
0.75:1 5.7 96.3 49.7±1.8 0.15 75 days 0.64±0.12

DLC (%) = [weight of CPT loaded ÷ (weight of carrier + weight of CPT or CPT prodrugs loaded)]

DLE (%) = (weight of loaded drug ÷ weight of input drug) X 100%

PDI: polydispersity index

Stability: no significant size change was observed during the time period tested in PBS solution at room temperature.